WuXi Biologics Statistics

Total Valuation

WuXi Biologics has a market cap or net worth of HKD 61.65 billion. The enterprise value is 60.60 billion.

Market Cap	61.65B
Enterprise Value	60.60B

Important Dates

The next estimated earnings date is Thursday, November 21, 2024.

Earnings Date	Nov 21, 2024
Ex-Dividend Date	n/a

Share Statistics

WuXi Biologics has 4.10 billion shares outstanding. The number of shares has decreased by -1.28% in one year.

Current Share Class	n/a
Shares Outstanding	4.10B
Shares Change (YoY)	-1.28%
Shares Change (QoQ)	-2.12%
Owned by Insiders (%)	0.37%
Owned by Institutions (%)	35.68%
Float	3.51B

Valuation Ratios

The trailing PE ratio is 23.30 and the forward PE ratio is 14.40. WuXi Biologics's PEG ratio is 1.68.

PE Ratio	23.30
Forward PE	14.40
PS Ratio	3.38
PB Ratio	1.43
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	1.68

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.91, with an EV/FCF ratio of -180.77.

EV / Earnings	21.43
EV / Sales	3.29
EV / EBITDA	11.91
EV / EBIT	16.35
EV / FCF	-180.77

Financial Position

The company has a current ratio of 2.91, with a Debt / Equity ratio of 0.10.

Current Ratio	2.91
Quick Ratio	2.40
Debt / Equity	0.10
Debt / EBITDA	0.96
Debt / FCF	-14.64
Interest Coverage	23.35

Financial Efficiency

Return on equity (ROE) is 7.20% and return on invested capital (ROIC) is 4.61%.

Return on Equity (ROE)	7.20%
Return on Assets (ROA)	3.98%
Return on Capital (ROIC)	4.61%
Revenue Per Employee	1.48M
Profits Per Employee	227,440
Employee Count	12,740
Asset Turnover	0.32
Inventory Turnover	5.35

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -68.89% in the last 52 weeks. The beta is 0.63, so WuXi Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.63
52-Week Price Change	-68.89%
50-Day Moving Average	15.45
200-Day Moving Average	14.41
Relative Strength Index (RSI)	41.33
Average Volume (20 Days)	62,060,268

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, WuXi Biologics had revenue of HKD 18.39 billion and earned 2.83 billion in profits. Earnings per share was 0.64.

Revenue	18.39B
Gross Profit	7.11B
Operating Income	3.71B
Pretax Income	3.93B
Net Income	2.83B
EBITDA	4.89B
EBIT	3.71B
Earnings Per Share (EPS)	0.64

Full Income Statement

Balance Sheet

The company has 10.24 billion in cash and 4.91 billion in debt, giving a net cash position of 5.33 billion or 1.30 per share.

Cash & Cash Equivalents	10.24B
Total Debt	4.91B
Net Cash	5.33B
Net Cash Per Share	1.30
Equity (Book Value)	47.97B
Book Value Per Share	10.52
Working Capital	13.98B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.46 billion and capital expenditures -3.79 billion, giving a free cash flow of -335.21 million.

Operating Cash Flow	3.46B
Capital Expenditures	-3.79B
Free Cash Flow	-335.21M
FCF Per Share	-0.08

Full Cash Flow Statement

Margins

Gross margin is 38.66%, with operating and profit margins of 20.16% and 15.38%.

Gross Margin	38.66%
Operating Margin	20.16%
Pretax Margin	21.34%
Profit Margin	15.38%
EBITDA Margin	26.57%
EBIT Margin	20.16%
FCF Margin	-1.82%

Dividends & Yields

WuXi Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.28%
Shareholder Yield	1.28%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.

Last Split Date	Nov 16, 2020
Split Type	Forward
Split Ratio	3

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a